EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Roxadustat in Kidney Transplant Recipients with ESA-Hyporesponsive Anemia: A Prospective Single-Center Cohort Study

Antonio Franco iD, Patricio Más-Serrano iD, Iván Beltrá-Picó iD, Elena de la Cruz, Noelia Balibrea, Nuria Bondia, Javier Perez-Contreras

Life · 13.05.2026 · 16 (5) · 815

DOI: 10.3390/life16050815 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Life, online erschienen am 13.05.2026. Verfasst von Antonio Franco und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, University General Hospital Dr. Balmis of Alicante, 03010 Alicante, Spain. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sociedad Valenciana de Nefrología.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, stimulates erythropoiesis. This prospective single-center, non-randomized, single-arm cohort study enrolled renal transplant recipients with refractory anemia, defined as hemoglobin (Hb) ≤10 g/dL despite receiving the maximum doses of erythropoiesis-stimulating agents for 12 weeks. The studied parameters were Hb, ferritin, iron saturation index, glomerular filtration rate (eGFR), and C-reactive protein (CRP). Follow-up assessments were conducted at 4, 8, and 12 weeks after starting Roxadustat. The primary endpoint was the proportion of patients achieving Hb > 11 g/dL at 12 weeks. Secondary endpoints included changes from baseline in studied parameters and adverse effects. Twenty recipients (11 male, 9 female) with a median age of 69.0 years and a median time post-transplant of 62.5 months were included. Median baseline eGFR was 16.5 mL/min/1.73 m2. At 12 weeks, 19 of 20 (95%) achieved Hb > 11 g/dL. Median Hb increased significantly from 9.1 g/dL to 11.5 g/dL, with a median individual change of +2.7 g/dL (IQR 1.7–3.4; p < 0.001). The only non-responder increased Hb from 9.5 to 10.2 g/dL. Ferritin decreased significantly over 12 weeks, whereas no statistically significant changes were observed in transferrin saturation, CRP, or eGFR. No serious adverse events were observed. In this prospective cohort, roxadustat was associated with short-term hemoglobin improvement and high Hb target attainment; however, these findings should be interpreted cautiously given the single-arm design and limited sample size.

Schlagwörter

Stichwörter der Autor:innen

refractory anemiarenal transplantroxadustat

Autor:innen und Institutionen

  • Department of Nephrology, University General Hospital Dr. Balmis of Alicante, 03010 Alicante, Spain.
  • Alicante Institute for Health and Biomedical Research (ISABIAL-FISABIO Foundation), 03010 Alicante, Spain.
  • Pharmacy Department, University General Hospital Dr. Balmis of Alicante, 03010 Alicante, Spain.

ORCID-Profile: Antonio Franco, Patricio Más-Serrano, Iván Beltrá-Picó

Förderung

  • Sociedad Valenciana de Nefrología

Zitieren

APA

Franco, A., Más-Serrano, P., Beltrá-Picó, I., de la Cruz, E., Balibrea, N., Bondia, N., & Perez-Contreras, J. (2026). Roxadustat in Kidney Transplant Recipients with ESA-Hyporesponsive Anemia: A Prospective Single-Center Cohort Study. Life, 16(5), 815. https://doi.org/10.3390/life16050815

Vancouver

Franco A, Más-Serrano P, Beltrá-Picó I, de la Cruz E, Balibrea N, Bondia N, et al. Roxadustat in Kidney Transplant Recipients with ESA-Hyporesponsive Anemia: A Prospective Single-Center Cohort Study. Life. 2026;16(5):815. doi:10.3390/life16050815

BibTeX
@article{Franco2026,
  author = {Franco, Antonio and Más-Serrano, Patricio and Beltrá-Picó, Iván and de la Cruz, Elena and Balibrea, Noelia and Bondia, Nuria and Perez-Contreras, Javier},
  title = {Roxadustat in Kidney Transplant Recipients with ESA-Hyporesponsive Anemia: A Prospective Single-Center Cohort Study},
  journal = {Life},
  year = {2026},
  volume = {16},
  number = {5},
  pages = {815},
  doi = {10.3390/life16050815}
}
Kostenlos starten →